Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy

Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1

(2021) Peter Ackerman et al.   AIDS

Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc

(2021) Ronald Rose et al.   AIDS

Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure–Response Analysis

(2020) Chakradhar V Lagishetty et al.   CTS-Clinical and Translational Science

Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir

(2020) Yagai Bouba et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Gp120 substitutions at positions associated with resistance to fostemsavir in treatment-naive HIV-1-positive individuals

(2020) Luciana Lepore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients

(2020) Francesco Saladini et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection

(2020) Michael Kozal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clearance of HIV infection by selective elimination of host cells capable of producing HIV

(2020) Min Li et al.   Nature Communications

Fostemsavir: A Novel Attachment Inhibitor for Patients With Multidrug-Resistant HIV-1 Infection

(2020) Kayla Hiryak et al.   ANNALS OF PHARMACOTHERAPY

Burden of disease in PLWH harboring a multidrug resistant virus: data from PRESTIGIO Registry

(2020) Laura Galli et al.   Open Forum Infectious Diseases

Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense® Entry assay

(2020) Margaret Gartland et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

2500. Fostemsavir Drug–Drug Interaction Profile, an Attachment Inhibitor and Oral Prodrug of Temsavir, for Heavily Treatment Experienced HIV-1-Infected Patients

(2019) Katy P Moore et al.   Open Forum Infectious Diseases

Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavir

(2018) Elodie Alessandri-Gradt et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Fostemsavir

(2018) Pedro Cahn et al.   Current Opinion in HIV and AIDS

Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir

(2017) Nicholas A. Meanwell et al.   JOURNAL OF MEDICINAL CHEMISTRY

Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529

(2017) Marie Pancera et al.   Nature Chemical Biology

Pharmacokinetics of Temsavir, the Active Moiety of the Prodrug Fostemsavir, in Subjects with Hepatic Impairment

(2017) Heather Sevinsky et al.   Open Forum Infectious Diseases

Inhibitors of HIV-1 attachment: The discovery and structure–activity relationships of tetrahydroisoquinolines as replacements for the piperazine benzamide in the 3-glyoxylyl 6-azaindole pharmacophore

(2016) Jacob J. Swidorski et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial

(2015) Jacob P Lalezari et al.   Lancet HIV

Activity of the HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068, against CD4-Independent Viruses and HIV-1 Envelopes Resistant to Other Entry Inhibitors

(2013) Zhufang Li et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068

(2013) N. Zhou et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Compartmental Absorption Modeling and Site of Absorption Studies to Determine Feasibility of an Extended-Release Formulation of an HIV-1 Attachment Inhibitor Phosphate Ester Prodrug

(2013) Jonathan Brown et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada

(2013) Hasina Samji et al.   PLoS One

In VitroAntiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068

(2012) Beata Nowicka-Sans et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, an Oral HIV-1 Attachment Inhibitor in HIV-1-Infected Subjects

(2012) R. E. Nettles et al.   JOURNAL OF INFECTIOUS DISEASES

Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Attachment 6. Preclinical and Human Pharmacokinetic Profiling of BMS-663749, a Phosphonooxymethyl Prodrug of the HIV-1 Attachment Inhibitor 2-(4-Benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoethanone (BMS-488043)

(2012) John F. Kadow et al.   JOURNAL OF MEDICINAL CHEMISTRY

Antiviral Activity, Pharmacokinetics, and Safety of BMS-488043, a Novel Oral Small-Molecule HIV-1 Attachment Inhibitor, in HIV-1-Infected Subjects

(2010) George J. Hanna et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VivoPatterns of Resistance to the HIV Attachment Inhibitor BMS-488043

(2010) Nannan Zhou et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1-Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study

(2010) Jean-Michel Molina et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES